2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
4
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Lung Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
563
Specimen Handling
493
Carboplatin
451
Magnetic Resonance Spectroscopy
444
Cyclophosphamide
418
Cisplatin
405
Radiotherapy
353
Bevacizumab
314
Gemcitabine
313
Paclitaxel
298
Biopsy
292
Drug Therapy
284
Blood Specimen Collection
248
Capecitabine
246
Oxaliplatin
241
fludarabine
239
Nivolumab
234
venetoclax
221
Injections
213
Docetaxel
211
Fluorouracil
206
Dexamethasone
188
Radiosurgery
182
Standard of Care
159
Rituximab
159
Pemetrexed
156
Surgical Procedures, Operative
148
atezolizumab
146
durvalumab
145
Leucovorin
140
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
2,2'-dithiodiethanesulfonic acid
×
Clear all
NCT05456256
2026-05-04
HARMONIC
Lantern Pharma Inc.
Phase 2
Recruiting
90 enrolled